Bishal Gyawali1,2,3, Rebecca Griffiths4, Andrew G Robinson1,2, Matthew D F McInnes5,6, Philippe L Bedard7, Christopher M Booth1,2,3,4. 1. Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, ON, Canada. 2. Department of Oncology, Queen's University, Kingston, ON, Canada. 3. Department of Public Health Sciences, Queen's University, Kingston, ON, Canada. 4. ICES, Queen's University, Kingston, ON, Canada. 5. Department of Radiology, University of Ottawa, Ottawa, ON, Canada. 6. Cinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. 7. Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON Canada.
Abstract
INTRODUCTION: Imaging is an integral component of active surveillance (AS) following orchiectomy for stage 1 non-seminoma (NSGCT) and seminoma germ cell tumors. In this population-based study, we describe use of imaging among patients with early-stage testicular cancer and evaluate whether they are concordant with guideline recommendations. METHODS: This is a population-based, retrospective cohort study to describe use of imaging among all patients with early-stage testicular cancer treated with AS in the Canadian province of Ontario. The Ontario Cancer Registry was linked to electronic records of treatment to identify use of chest and abdomen/pelvis imaging. Data from 2000-2010 were included, with followup for up to five years for patients with non-seminoma and 10 years for patients with seminoma. The key outcome of interest was the frequency of imaging at temporal milestones following orchiectomy. Compared to the most contemporaneous guidelines in Ontario, any discordant frequency of imaging was defined as underuse or overuse. Substantial under- or overuse was defined as >1 imaging test less/ more than what was recommended during a 12-month period. RESULTS: The study population included 569 patients with NSGCT (median age 28) and 1107 with seminoma (median age 37). Among patients with NSGCT, adherence with body imaging was low in years 1-3 of surveillance (range 26-37%, predominantly underuse) and higher in years 4-5 (63-67%, predominantly overuse). Adherence with chest imaging was even lower (range 11-34% during years 1-5). Among patients with seminoma, adherence with abdominal and chest imaging was relatively stable and comparable throughout the 10-year followup period (range 23-47% abdomen and 28-47% chest). Multivariable analysis confirmed that underuse of imaging was more common in recent years. NSGCT histology was associated with underuse in years 1-2 but overse in years 3-5. CONCLUSIONS: In routine clinical practice, patients with testicular cancer commonly receive imaging discordant to the protocol for AS, with a substantial proportion receiving both under- and overuse at various times during surveillance followup.
INTRODUCTION: Imaging is an integral component of active surveillance (AS) following orchiectomy for stage 1 non-seminoma (NSGCT) and seminoma germ cell tumors. In this population-based study, we describe use of imaging among patients with early-stage testicular cancer and evaluate whether they are concordant with guideline recommendations. METHODS: This is a population-based, retrospective cohort study to describe use of imaging among all patients with early-stage testicular cancer treated with AS in the Canadian province of Ontario. The Ontario Cancer Registry was linked to electronic records of treatment to identify use of chest and abdomen/pelvis imaging. Data from 2000-2010 were included, with followup for up to five years for patients with non-seminoma and 10 years for patients with seminoma. The key outcome of interest was the frequency of imaging at temporal milestones following orchiectomy. Compared to the most contemporaneous guidelines in Ontario, any discordant frequency of imaging was defined as underuse or overuse. Substantial under- or overuse was defined as >1 imaging test less/ more than what was recommended during a 12-month period. RESULTS: The study population included 569 patients with NSGCT (median age 28) and 1107 with seminoma (median age 37). Among patients with NSGCT, adherence with body imaging was low in years 1-3 of surveillance (range 26-37%, predominantly underuse) and higher in years 4-5 (63-67%, predominantly overuse). Adherence with chest imaging was even lower (range 11-34% during years 1-5). Among patients with seminoma, adherence with abdominal and chest imaging was relatively stable and comparable throughout the 10-year followup period (range 23-47% abdomen and 28-47% chest). Multivariable analysis confirmed that underuse of imaging was more common in recent years. NSGCT histology was associated with underuse in years 1-2 but overse in years 3-5. CONCLUSIONS: In routine clinical practice, patients with testicular cancer commonly receive imaging discordant to the protocol for AS, with a substantial proportion receiving both under- and overuse at various times during surveillance followup.
Authors: C Kollmannsberger; S Tyldesley; C Moore; K N Chi; N Murray; S Daneshmand; P Black; G Duncan; B Hayes-Lattin; C Nichols Journal: Ann Oncol Date: 2010-10-06 Impact factor: 32.976
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Int J Surg Date: 2014-07-18 Impact factor: 6.071
Authors: Timothy Gilligan; Daniel W Lin; Rahul Aggarwal; David Chism; Nicholas Cost; Ithaar H Derweesh; Hamid Emamekhoo; Darren R Feldman; Daniel M Geynisman; Steven L Hancock; Chad LaGrange; Ellis G Levine; Thomas Longo; Will Lowrance; Bradley McGregor; Paul Monk; Joel Picus; Phillip Pierorazio; Soroush Rais-Bahrami; Philip Saylor; Kanishka Sircar; David C Smith; Katherine Tzou; Daniel Vaena; David Vaughn; Kosj Yamoah; Jonathan Yamzon; Alyse Johnson-Chilla; Jennifer Keller; Lenora A Pluchino Journal: J Natl Compr Canc Netw Date: 2019-12 Impact factor: 11.908
Authors: J Oldenburg; S D Fosså; J Nuver; A Heidenreich; H-J Schmoll; C Bokemeyer; A Horwich; J Beyer; V Kataja Journal: Ann Oncol Date: 2013-10 Impact factor: 32.976
Authors: D Scott Ernst; Penny Brasher; Peter M Venner; Piotr Czaykowski; Malcolm J Moore; Leonard Reyno; Eric Winquist; Roanne Segal; Desiree Hao Journal: Can J Urol Date: 2005-04 Impact factor: 1.344
Authors: Phillip M Pierorazio; Joseph G Cheaib; Hiten D Patel; Mohit Gupta; Ritu Sharma; Allen Zhang; Giorgia Tema; Eric B Bass Journal: J Urol Date: 2020-09-11 Impact factor: 7.450
Authors: Mitchell M Huang; Zhuo T Su; Joseph G Cheaib; Michael J Biles; Mohamad E Allaf; Hiten D Patel; Phillip M Pierorazio Journal: Eur Urol Focus Date: 2020-07-06
Authors: Gordon J Rustin; Graham M Mead; Sally P Stenning; Paul A Vasey; Nina Aass; Robert A Huddart; Michael P Sokal; Jonathan K Joffe; Stephen J Harland; Sarah J Kirk Journal: J Clin Oncol Date: 2007-04-10 Impact factor: 44.544
Authors: Ernest Kaufmann; Luca Antonelli; Peter Albers; Clint Cary; Silke Gillessen Sommer; Axel Heidenreich; Christoph Oing; Jan Oldenburg; Phillip Martin Pierorazio; Andrew J Stephenson; Christian Daniel Fankhauser Journal: Eur Urol Open Sci Date: 2022-09-07